Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 31,368 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose 2 Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

NCT03335254
View directory record Official record
Conditions
Hypogonadism, Hypogonadism, Male, Gonadal Disorders, Endocrine System Diseases, Testosterone Deficiency
Interventions
TSX-011
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 4 Interventional

Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)

NCT01733394
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand", lamotrigine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Des Moines, Iowa • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

NCT01896856
View directory record Official record
Conditions
Previously Treated Metastatic Colorectal Cancer
Interventions
SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 23, 2026, 9:10 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

NCT03140722
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
vadadustat, epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Bakersfield, California • Elk Grove, California • Encino, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Not applicable Interventional

Treatment of Opioid Use: Medication Adherence Therapy

NCT03567356
View directory record Official record
Conditions
Opioid Dependence, Opioid-Related Disorders
Interventions
MAT-PLUS "Helping Hands"
Other
Lead sponsor
Potomac Health Foundations
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

NCT00083551
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

NCT05260437
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NCT01396239
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AVI-4658 (Eteplirsen), Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 9:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

NCT04409639
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia (CMML)
Interventions
Cobimetinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Portland, Oregon • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human Study Of Increasing Oral Doses Of PF-04634817

NCT01098877
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817 Placebo, PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

A Study of LY3471851 in Participants With Psoriasis

NCT04119557
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, LY3471851
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
North Little Rock, Arkansas • Encinitas, California • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer

NCT00039624
View directory record Official record
Conditions
Prostate Cancer
Interventions
Brachytherapy
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy

NCT02061423
View directory record Official record
Conditions
Breast Cancer
Interventions
HER-2 pulsed Dendritic Cell Vaccine
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies

NCT00822523
View directory record Official record
Conditions
Muscle Strength, Botulinum Toxins, Type A
Interventions
Botulinum Toxin, Type A, Saline
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 54 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

NCT00261846
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
29
States / cities
Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Impairment, Healthy
Interventions
PF-06882961 20 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Testosterone on Prostate Tissue (ACYP-1)

NCT00161486
View directory record Official record
Conditions
Hypogonadism, Contraception
Interventions
Testosterone gel, Acyline, Placebo acyline, Placebo Testosterone gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 23, 2026, 9:10 PM EDT
Active, not recruiting Phase 2 Interventional

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

NCT03546686
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Evaluation of KX2-391 in Patients With Advanced Malignancies

NCT00658970
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
KX2-391
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

NCT01808573
View directory record Official record
Conditions
HER2+ Metastatic Breast Cancer (MBC)
Interventions
neratinib, capecitabine, lapatinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 23, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02940886
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
114
States / cities
Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 23, 2026, 9:10 PM EDT